Pregnancy failure is extremely distressing for couples who desire to have children. Preeclampsia and HELLP syndrome (hemolysis, elevated liver enzymes, low platelet counts) are leading causes of maternal and perinatal mortality as well as extensive morbidity.
Besides venous or arterial thromboembolic manifestations, pregnancy failure and pregnancy complications are clinical criteria for the diagnosis of antiphospholipid syndrome. (1) Analogous to this acquired thrombophilic syndrome, in the nineties of the last century, the association between inherited thrombophilic disorders and miscarriage was first detected in family studies of probands, who were identified because of their history of venous thromboembolism.(2-4) Since then, many studies have confirmed the relationship between inherited thrombophilia and pregnancy failure and complications.(5;6) The potential association with thrombophilia has increased the number of investigations in couples with recurrent miscarriage and other pregnancy complications. Moreover, hematologists and thrombosis specialists are increasingly being consulted by women who have some form of thrombophilia and who were tested by gynaecologists in the context of pregnancy complications.(7) Also, a presumed benefit of antithrombotic therapy, in the absence of perceived harms, has led many clinicians to prescribe low-molecular-weight heparin, aspirin, or both to women with placentamediated pregnancy complications including recurrent miscarriage. Here, I debate that with the currently available best evidence, there is no role for low-molecular-weight heparin in women with recurrent miscarriage.
Definitions of several forms of pregnancy failure have not been used consistently.
Recently, a revision of the nomenclature of early pregnancy events was proposed that applies ultrasound for accurate clinical assessment and diagnosis.(8) Fetal loss is defined as the previous identification of crown-rump length and fetal heart activity followed by loss of heart activity. Recurrent miscarriage is defined as 3 early consecutive losses or 2 late pregnancy losses. Early miscarriage comprises the ultrasound definition of intrauterine pregnancy with reproducible evidence of lost fetal heart activity, and/or failure of increased crown-rump length over one week, or persisting presence of empty sac, at less than 12 weeks gestation. From here it follows logically that late fetal loss is defined as loss after 12 weeks gestational age, where fetal measurement was followed by loss of fetal heart activity. It is of note that most studies have used other than the abovementioned definitions.
It is unlikely that hypercoagulability with thrombosis of placental vasculature is the main pathophysiological substrate for the association between acquired and inherited thrombophilia, in particular for early miscarriage in the context of antiphospholipid syndrome. (9) In vitro experiments have shown that antiphospholipid antibodies inhibit extravillous trophoblast differentiation and subsequent placentation. (10) This "nonprothrombotic theory" is supported by the observation that both heparin and aspirin attenuate trophoblast apoptosis in vitro. (11) The fact that it is not biologically plausible that an assumed thrombotic component in women with inherited thrombophilia plays a role until 10 to 12 weeks of gestation, when the placental vasculature has been developed, leaves unexplained why the vast majority of women with recurrent miscarriage have early losses. For the common forms of inherited thrombophilia, experimental models to study trophoblast differentiation and early placentation are lacking. However, thrombomodulin-deficient mice, which lack the important natural anticoagulant protein C pathway, are unable to carry their fetuses beyond 8.5 weeks gestational age, and dead fetuses are usually resorbed within 24 hours. (12) Elegant experiments have shown that fetal demise is caused by tissue factor-dependent activation of blood coagulation at the feto-maternal interface. Activated coagulation factors were found to induce cell death and inhibit growth of trophoblast cells. Administration of heparin or aspirin to the mice delayed absorption of their embryos but was unable to restore trophoblast differentiation and overcome the growth defect of these thrombomodulin deficient embryos.
From the above it can be concluded that mere hypercoagubility is unlikely to be the sole mechanism by which thrombophilia increases the risk for pregnancy failure, most notably early losses, whereas effects on trophoblast differention and early placentation may be involved through yet unknown mechanisms. Interestingly, both aspirin and heparin appear to affect these early trophoblast and placentation mechanisms in vitro and in a hypercoagulability mouse model.
Evaluating effectiveness of interventions: observational research and randomized experiments
Observational research is a valid method to establish an association or causal relationship between thrombophilia and pregnancy complications. (13;14) Obviously, in interpreting results from association studies it is necessary to take into account whether potential bias and confounders have been sufficiently addressed in the design and execution of the study, or the analysis of the data. For clinicians the consistency and strengths of associations, the biological plausibility in terms of potential mechanisms and, crucially, whether these should lead to targeted therapy are likely to be most relevant.
Contrary to investigations on associations, a randomized experimental approach is absolutely necessary for establishing whether therapy is beneficial in women with thrombophilia and pregnancy complications, in order to avoid the problem of confounding by indication. When judging a randomized controlled trial for its validity, internal and external validity should be considered. Of course, the intervention under study should have a valid comparator, i.e. current standard of care or, most preferable, placebo. Concealment of allocation, which means that the physician that enters a patient into a trial cannot predict the treatment the patient will receive, is the key quality component in the randomization process. (15) In fact, inadequate concealment overestimates effects of interventions in controlled trials by about 30%. (16;17) Furthermore, other quality parameters are blinding of patient and doctor, blinded outcome assessment, minimal loss to follow-up, intention-to-treat analysis and provision of similar care in both interventions arms. External validity items include the possibility to generalize findings in the study population to the patient population of interest.
Evidence from interventional studies of (low-molecular-weight) heparin in women with recurrent miscarriage
The Table lists the currently available evidence from randomized trials that investigated the effect of any type of heparin on pregnancy loss, compared to no heparin, in women with a history of recurrent miscarriage, stratified for women with antiphospholipid syndrome and type of heparin and women with unexplained recurrent miscarriage (lowmolecular-weight heparin only). Pregnancy loss was chosen as an outcome in this Table, because not all trials have reported live birth rates. Generally, the number of women that have been studied by this adequate study design is remarkably low.
Recurrent miscarriage in women with antiphospholipid syndrome
In women with recurrent miscarriage based on the antiphospholipid syndrome, a wellperformed randomized controlled trial showed an absolute increase of live birth rate from 41% to 72% with the use of a combination of low-dose unfractionated heparin and lowdose aspirin, compared to aspirin alone.(18) Two other trials also showed a benefit of a combination of unfractionated heparin and aspirin compared to aspirin alone (Table) . ( The effect of low-molecular-weight heparin on pregnancy loss in women with inherited thrombophilia in the absence of a history of recurrent miscarriage has been discussed elsewhere, and is not the focus of this debate.(13;37)
Unexplained recurrent miscarriage
Recently, randomized controlled trials that investigated the efficacy of low-molecularweight heparin in women with unexplained recurrent miscarriage have been published, and are listed in the Table.( for the combined intervention compared to placebo, and 1.22 (95%CI: 0.69 to 2.16) for aspirin, with corresponding absolute difference in live birth rates of 16.3% (95%CI: −18.2 to 50.8) and 11.8% (95%CI: −21.1 to 44.6) respectively. The possibility that one or both of these interventions might be beneficial in such women warrants further study in adequately powered, controlled trials.
Conclusions
For women with APS, unfractionated heparin combined with aspirin has been shown to be superior to aspirin alone, and there is very limited evidence of the effect of aspirin alone in this study population. This effect has not been confirmed in two studies trials that investigated the use of low-molecular-weight heparin in addition to aspirin. For women with inherited thrombophilia and recurrent miscarriage, no evidence from randomized controlled trials is currently available to justify this therapy. Although two recent studies have reported a beneficial effect of low-molecular-weight heparin compared to no pharmacological intervention in women with unexplained recurrent miscarriage, two high-quality randomized controlled trials were unable to demonstrate benefit of low-molecular-weight heparin combined with aspirin in women with unexplained recurrent miscarriage. 
